miRecule Inc.
Wednesday, June 05, 2024
Company Presentation
![Platform for Therapeutics](https://cdn.asp.events/CLIENT_BIO_7BB99CBA_BAD1_B8C8_CF9F25DA29A80CC6/sites/BIOIC-2024/media/icons/seminars/blank.png)
Company Presentation Theater 4
miRecule’s approach to drug design revolves around using a platform which integrates genomic sequencing, expression, and prognostic data from patients with high throughput screening of RNA to identify its drug candidates. The resulting Antibody-RNA Conjugates (ARCs), present a very promising opportunity that will significantly expand the targetome of antibody-based cancer therapy. RNA-based therapeutics hold out the promise of significantly lower cost-of-goods and the ability to rapidly modify and change (plug and play) therapeutics from an existing ARC scaffold. In 2022, miRecule entered into a strategic collaboration with Sanofi to develop a best-in-class nanobody-RNA conjugate to treat the second most common form of muscular dystrophy, Facioscapulohumeral Muscular Dystrophy (FSHD). Beyond this program, miRecule's own proprietary lead program, MC-30, targets the 6th most common form of cancer, head and neck cancer afflicting more than 30,000 patients annually.
![miRecule Inc.](https://www.abstractscorecard.com/uploads/Tasks/upload/21754/XDQDGWMO-1783767-1-JPG.png)
Company Website:
https://mirecule.com/team/
Lead Product in Development:
miRecule's own proprietary lead program, MC-30, targets the 6th most common form of cancer, head and neck cancer afflicting more than 30,000 patients annually, and addresses an estimated potential market opportunity of $3.2bil.
Number Of Unlicensed Products (For Which You Are Seeking Partners):
multiple
Company HQ City
Gaithersburg
Company HQ State
MD
Company HQ Country
United States
CEO/Top Company Official
Anthony Saleh
Development Phase of Primary Product
Pre-Clinical
Primary Speaker